Picture of Ajanta Pharma logo

AJANTPHARM — Ajanta Pharma News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

India's Ajanta Pharma rises as Motilal Oswal sees strong gains from new weight-loss drug

** Ajanta Pharma AJPH.NS rises 2.5% to 2,757.30 rupees

** Motilal Oswal says AJPH's partnership with Biocon BION.NS to source weight-loss drug semaglutide is "meaningful step" towards introducing newer therapies, way for AJPH to secure market share

** Forecasts potential annualised sales from semaglutide in Asia and Africa at $25-30 mln from H2 FY28, EBITDA margin of 50-55%

** Expects AJPH's overall revenue and profit to grow at 11% and 16% CAGR, respectively, over FY26-28

** Reiterates "buy" rating on AJPH with PT of 3,145 rupees

** Avg rating of 13 analysts is "buy"; median PT is 3,120 rupees - data compiled by LSEG

** YTD, AJPH down 6% vs pharma index's .NIPHARM 3.9% decline

(Reporting by Kashish Tandon in Bengaluru)

((Kashish.tandon@thomsonreuters.com))

Recent news on Ajanta Pharma

See all news